...
首页> 外文期刊>Clinical therapeutics >A 2-week, multicenter, randomized, double-blind, double-dummy, add-on study of the effects of titration on tolerability of tramadol/acetaminophen combination tablet in Korean adults with knee osteoarthritis pain.
【24h】

A 2-week, multicenter, randomized, double-blind, double-dummy, add-on study of the effects of titration on tolerability of tramadol/acetaminophen combination tablet in Korean adults with knee osteoarthritis pain.

机译:一项为期2周,多中心,随机,双盲,双虚拟的附加研究,研究了滴定对韩国成人膝关节骨关节炎疼痛中曲马多/对乙酰氨基酚片剂的耐受性的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Combined tramadol/acetaminophen is used to treat pain related to osteoarthritis. However, adverse events (AEs) leading to discontinuation can occur. Dose titration may decrease the risk for AEs. OBJECTIVE: The aim of this study was to assess the effect of tramadol/acetaminophen titration on the development of AEs leading to treatment discontinuation in patients with knee osteoarthritis. METHODS: This 2-week, multicenter, randomized, double-blind, double-dummy, add-on study was conducted at 12 tertiary referral university hospitals in the Republic of Korea. Patients aged 35 to 75 years with knee osteoarthritis receiving a stable dose of NSAIDs and with a daily mean pain-intensity score of > or = 4 on a numeric rating scale (NRS) (0 = no pain to 10 = worst pain) during the 48 hours prior to enrollment were eligible. Patients were randomly assigned to receive 1 tablet of tramadol/acetaminophen 37.5/325 mg QD and 1 placebo BID for 3 days, followed by 1 active tablet BID and 1 placebo QD for 4 days, followed by 1 active tablet TID for 7 days (titration group) or 1 tablet of combined tramadol 37.5 mg/acetaminophen 325 mg TID for 14 days (nontitration group). The primary outcome measure was the rate of treatment discontinuation due to AEs. Secondary outcome measures were time to discontinuation due to AEs, prevalences and characteristics of AEs, decrease from baseline in pain intensity as measured on the NRS, and change in the Korean version of the Western Ontario and McMaster Universities (K-WOMAC) index score (scale: 0 = best to 100 = worst). RESULTS: A total of 250 patients were enrolled (92.0% female; mean [SD] age, 60.2 [7.8] years; mean [SD] weight, 60.0 [9.2] kg [range, 37.5-90.7 kg]; all Korean). The discontinuation rate was significantly lower in the titration group than in the nontitration group (10.5% vs 26.2%; P < 0.001). The Kaplan-Meier survival curve showed that the rates of discontinuation due to AEs were similar in the 2 groups up to day 2, but thereafter the discontinuation rate wassignificantly lower in the titration group. The most common AEs were nausea (12.1% and 24.6% in the titration and nontitration groups, respectively; P = 0.008), vomiting (4.0% and 17.2%; P < 0.001), and dizziness (9.7% and 22.1%; P = 0.005). No serious AEs were reported in either group. Tramadol/acetaminophen use was associated with a similar decrease from baseline in pain in both the titration and nontitration groups (mean [SD] Delta: NRS, -1.60 [1.62] vs -1.68 [1.58]; total K-WOMAC, -12.86 [13.73] vs -12.52 [16.58]). CONCLUSIONS: In this population of Korean patients with knee osteoarthritis pain managed with a stable dose of NSAIDs, titration of tramadol/acetaminophen over 12 days was associated with improved tolerability and a significantly lower discontinuation rate compared with nontitration. Both regimens significantly reduced from baseline associated with osteoarthritis.
机译:背景:曲马多/对乙酰氨基酚联合用于治疗与骨关节炎有关的疼痛。但是,可能会发生导致停药的不良事件(AE)。剂量滴定可降低发生AE的风险。目的:本研究的目的是评估曲马多/对乙酰氨基酚滴定对导致膝关节骨关节炎患者停药的不良事件发展的影响。方法:在韩国的12家三级转诊大学医院中进行了为期2周的多中心,随机,双盲,双虚拟,附加研究。 35至75岁的膝骨关节炎患者在治疗期间接受稳定剂量的NSAID,并且每日平均疼痛强度评分在数字评分量表(NRS)上大于或等于4(0 =无疼痛至10 =最严重疼痛)。入学前48小时符合资格。患者被随机分配接受1片曲马多/对乙酰氨基酚37.5 / 325 mg QD和1安慰剂BID治疗3天,然后接受1片活性片剂BID和1安慰剂QD治疗4天,然后接受1片活性药物TID 7天(滴定组)或1片曲马多37.5 mg /对乙酰氨基酚325 mg TID联合治疗14天(非滴定组)。主要结果指标是由于不良事件导致的治疗中止率。次要结局指标包括因不良事件而终止治疗的时间,不良事件的发生率和特征,使用NRS测量的疼痛强度从基线水平降低,以及韩文版的西安大略省和麦克马斯特大学(K-WOMAC)指数得分的变化(标度:0 =最佳到100 =最差)。结果:共纳入250例患者(女性92.0%;平均[SD]年龄:60.2 [7.8]岁;平均[SD]体重:60.0 [9.2] kg [范围:37.5-90.7 kg];全部为韩国人)。滴定组的停药率显着低于非滴定组(10.5%比26.2%; P <0.001)。 Kaplan-Meier生存曲线表明,直至第2天,两组中由于AE引起的停药率相似,但此后滴定组的停药率显着降低。最常见的不良事件为恶心(滴定和非滴定组分别为12.1%和24.6%; P = 0.008),呕吐(4.0%和17.2%; P <0.001)和头晕(9.7%和22.1%; P = 0.005)。两组均未报告严重不良事件。在滴定和非滴定组中,曲马多/对乙酰氨基酚的使用与疼痛的基线下降相似(平均[SD] Delta:NRS,-1.60 [1.62] vs -1.68 [1.58]; K-WOMAC总值,-12.86 [ 13.73] vs -12.52 [16.58])。结论:在韩国人群中,使用稳定剂量的非甾体抗炎药治疗的膝关节骨关节炎疼痛患者,曲马多/对乙酰氨基酚滴定超过12天与耐受性改善相关,与非滴定相比,停药率显着降低。两种治疗方案均较与骨关节炎相关的基线水平明显降低。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号